TY - JOUR
T1 - Host immunosurveillance contributes to the control of erbB-2 overexpression in HLA-A2-breast-cancer patients
AU - Nisticò, Paola
AU - Mottolese, Marcella
AU - Cascioli, Simona
AU - Benevolo, Maria
AU - Del Bello, Duilia
AU - Di Modugno, Francesca
AU - Rubiu, Oriana
AU - Gentile, Francesco Paolo
AU - Botti, Claudio
AU - Venturo, Irene
AU - Natali, Pier Giorgio
PY - 1999
Y1 - 1999
N2 - Overexpression of gp185(erbB-2) has been associated with reduced survival in breast-cancer patients. Our earlier results, now confirmed in a larger cohort of patients (798), evidenced that the HLA-A2 allele may participate in the modulation of the erbB-2 tumor phenotype in vivo. In the present study, we evaluated other clinico-biopathologic parameters possibly involved in the host immune response against erbB-2. Localization of the CD3+ T-cell infiltrate was taken into consideration in 705 primary breast tumors, and expression of HLA-class-I and HLA-A2 antigens was evaluated in a subgroup of 170 frozen primary tumors of HLA-A2-positive patients. The presence or the absence of HLA-class-I and HLA-A2 antigens in primary tumors did not correlate with erbB-2 expression. However, HLA-A2-positive tumors preferentially showed intratumoral lymphocyte localization, whereas the lesions displaying undetectable HLA-class-I expression showed peritumoral CD3+ T-cell localization. Taking into account erbB-2 immunoreactivity, we found that the relationship between HLA-A2 expression and intratumoral CD3+ T-lymphocyte localization is significant only in the erbB-2 negative subset, whereas the relationship between lack of HLA-class-I expression and peritumoral CD3+ T-lymphocyte localization is significant only in the erbB- 2-positive subset. These data provide novel in vivo evidence of the possible contribution of the host immune system to control of erbB-2 oncogene overexpression in breast cancer.
AB - Overexpression of gp185(erbB-2) has been associated with reduced survival in breast-cancer patients. Our earlier results, now confirmed in a larger cohort of patients (798), evidenced that the HLA-A2 allele may participate in the modulation of the erbB-2 tumor phenotype in vivo. In the present study, we evaluated other clinico-biopathologic parameters possibly involved in the host immune response against erbB-2. Localization of the CD3+ T-cell infiltrate was taken into consideration in 705 primary breast tumors, and expression of HLA-class-I and HLA-A2 antigens was evaluated in a subgroup of 170 frozen primary tumors of HLA-A2-positive patients. The presence or the absence of HLA-class-I and HLA-A2 antigens in primary tumors did not correlate with erbB-2 expression. However, HLA-A2-positive tumors preferentially showed intratumoral lymphocyte localization, whereas the lesions displaying undetectable HLA-class-I expression showed peritumoral CD3+ T-cell localization. Taking into account erbB-2 immunoreactivity, we found that the relationship between HLA-A2 expression and intratumoral CD3+ T-lymphocyte localization is significant only in the erbB-2 negative subset, whereas the relationship between lack of HLA-class-I expression and peritumoral CD3+ T-lymphocyte localization is significant only in the erbB- 2-positive subset. These data provide novel in vivo evidence of the possible contribution of the host immune system to control of erbB-2 oncogene overexpression in breast cancer.
UR - http://www.scopus.com/inward/record.url?scp=0032786238&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0032786238&partnerID=8YFLogxK
U2 - 10.1002/(SICI)1097-0215(19991222)84:6<598::AID-IJC10>3.0.CO;2-7
DO - 10.1002/(SICI)1097-0215(19991222)84:6<598::AID-IJC10>3.0.CO;2-7
M3 - Article
C2 - 10567905
AN - SCOPUS:0032786238
VL - 84
SP - 598
EP - 603
JO - International Journal of Cancer
JF - International Journal of Cancer
SN - 0020-7136
IS - 6
ER -